Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Shares Climb 8.7% – Here’s What HappenedDefense World · Sep 27, 2026
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing PlatformBusiness Wire · Sep 8, 2026
Lineage Cell Therapeutics Q2 Earnings Call HighlightsMarketBeat · Aug 9, 2026
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 7, 2026
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research · Aug 6, 2026
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire · Aug 6, 2026Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.03 | -$0.03 | Miss |
| May 12, 2026 | -$0.02 | -$0.03 | Miss |
| Mar 5, 2026 | -$0.04 | $0.00 | Beat |
| Nov 6, 2025 | -$0.02 | -$0.13 | Miss |
| Aug 12, 2025 | -$0.02 | -$0.01 | Beat |
| May 13, 2025 | -$0.02 | -$0.02 | Beat |